A Phase I, Open-label, Multi-center, Single-dose Study to Evaluate the Pharmacokinetics of ABL001 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Asciminib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 18 Jul 2017 Status changed from recruiting to completed.
- 23 Feb 2017 Planned End Date changed from 1 May 2018 to 4 May 2018.
- 23 Feb 2017 Planned primary completion date changed from 1 May 2018 to 4 May 2018.